NASDAQ:CTOR Citius Oncology (CTOR) Stock Price, News & Analysis $4.71 -0.58 (-10.96%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$4.88 +0.17 (+3.50%) As of 07/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Citius Oncology Stock (NASDAQ:CTOR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Citius Oncology alerts:Sign Up Key Stats Today's Range$4.60▼$5.2450-Day Range$0.85▼$5.3252-Week Range$0.55▼$6.19Volume544,120 shsAverage Volume1.25 million shsMarket Capitalization$337.00 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company Overview Citius Oncology (NASDAQ:CTOR) is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted cancer therapies. Established as a spin-out from Citius Pharmaceuticals in 2021, the firm leverages proprietary DNA-based therapeutic platforms to create novel oncology agents. Its mission is to address critical unmet needs in solid tumors by advancing candidates that combine precise tumor targeting with innovative mechanisms of action. The company’s pipeline comprises multiple clinical-stage programs, including a DNA-intercalating small molecule designed to induce tumor cell death, a novel chlorotoxin-derived targeting peptide conjugate aimed at selectively binding and penetrating malignant tissue, and an immune-modulating biologic that activates innate pathways to enhance antitumor responses. These candidates are being evaluated across indications such as glioblastoma, pancreatic cancer and hepatic metastases. In addition to in-house research and development, Citius Oncology engages in strategic partnerships with academic institutions and contract development organizations to accelerate preclinical and clinical studies. The company has established scalable manufacturing processes compliant with current Good Manufacturing Practices (cGMP) and is pursuing regional collaborations to support regulatory filings and market access in North America and Europe. The leadership team brings extensive experience from major pharmaceutical and biotechnology companies, with expertise spanning oncology research, clinical development, manufacturing and regulatory affairs. Supported by a scientific advisory board of oncologists and translational researchers, the management team is focused on advancing its pipeline through key clinical milestones and preparing for eventual commercialization.AI Generated. May Contain Errors. Read More Citius Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreCTOR MarketRank™: Citius Oncology scored higher than 8% of companies evaluated by MarketBeat, and ranked 886th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingCitius Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCitius Oncology has only been the subject of 2 research reports in the past 90 days.Read more about Citius Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCitius Oncology has a P/B Ratio of 7.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CTOR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCitius Oncology does not currently pay a dividend.Dividend GrowthCitius Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CTOR. News and Social Media3.0 / 5News Sentiment0.37 News SentimentCitius Oncology has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Citius Oncology this week, compared to 0 articles on an average week.Search Interest6 people have searched for CTOR on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Citius Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Citius Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.57% of the stock of Citius Oncology is held by insiders.Percentage Held by Institutions70.52% of the stock of Citius Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Citius Oncology's insider trading history. Receive CTOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CTOR Stock News HeadlinesCitius Oncology (NASDAQ:CTOR) Stock Price Up 1.9% - Here's WhyJuly 5 at 3:21 AM | americanbankingnews.comCitius Oncology Regains Nasdaq Compliance June 2025June 27, 2025 | tipranks.comElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025. | Banyan Hill Publishing (Ad)Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025June 17, 2025 | prnewswire.comCitius Oncology stock soars on distribution dealJune 9, 2025 | in.investing.comMaxim Group Downgrades Citius Oncology (CTOR)May 24, 2025 | msn.comCitius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | prnewswire.comCitius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near FutureMay 7, 2025 | finance.yahoo.comSee More Headlines CTOR Stock Analysis - Frequently Asked Questions How have CTOR shares performed this year? Citius Oncology's stock was trading at $1.15 at the beginning of the year. Since then, CTOR shares have increased by 309.6% and is now trading at $4.71. How were Citius Oncology's earnings last quarter? Citius Oncology, Inc. (NASDAQ:CTOR) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. How do I buy shares of Citius Oncology? Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Citius Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC). Company Calendar Last Earnings5/14/2025Today7/07/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTOR Previous SymbolNASDAQ:CTOR CIK1851484 Webwww.citiusonc.com Phone347-627-0058FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside-36.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on Equity-53.88% Return on Assets-18.86% Debt Debt-to-Equity Ratio0.11 Current Ratio0.36 Quick Ratio0.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book7.36Miscellaneous Outstanding Shares71,552,000Free Float68,282,000Market Cap$337.01 million OptionableN/A Beta3.06 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:CTOR) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.